The hidden cost of deferred portfolio decisions

In most life sciences organizations, the most expensive decisions are not the ones that get made — they are the ones that get deferred. A go/no-go decision that sits in committee for six weeks does not simply delay an outcome. It consumes resources, narrows options, and increases the cost of being wrong.

The problem is structural. Portfolio governance processes are often designed to ensure thoroughness, not speed. Review cycles are long. Escalation paths are unclear. The incentive to defer — to gather more data, to wait for a cleaner signal — is almost always stronger than the incentive to decide.

What organizations rarely calculate is the compounding cost of that deferral. Every week a program continues without a clear mandate, it consumes budget, headcount, and management attention that could be directed elsewhere. Every week a termination decision is delayed, the sunk cost grows and the political difficulty of stopping increases.

Building a culture that decides requires more than process redesign. It requires leadership teams that are willing to make decisions with incomplete information, governance structures that reward decisiveness, and portfolio frameworks that make the cost of deferral visible.

The organizations that do this well share a common characteristic: they treat decision velocity as a strategic asset, not an operational detail. They understand that in a competitive environment, the ability to reallocate resources quickly is itself a source of advantage.